TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07231419: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Sponsor: Vertex Pharmaceuticals Incorporated · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 734 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$14,655,536

Rescue Site Savings

+$9,696,896

Unlock Full NCT07231419 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07231419 Rescue Dossier →